Get the Stockscreener App
6.04
0.49%
-0.03
After Hours:
6.09
0.05
+0.83%
Insight Molecular Diagnostics Inc stock is traded at $6.04, with a volume of 67,299.
It is down -0.49% in the last 24 hours and down -8.90% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$6.07
Open:
$6.06
24h Volume:
67,299
Relative Volume:
1.02
Market Cap:
$173.13M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-18.38%
1M Performance:
-8.90%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.9202
$6.24
1-Week Range:
$5.82
$7.5616
52-Week Range:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.04 | 173.99M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
587.48 | 215.18B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
227.39 | 156.94B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.91 | 55.05B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
151.25 | 41.12B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
224.90 | 36.97B | 15.90B | 1.28B | 2.21B | 7.2842 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
Will Insight Molecular Diagnostics Inc. (7OC0) stock remain on Wall Street radarJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock gain from green policiesQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Can Insight Molecular Diagnostics Inc. (7OC0) stock sustain institutional flowsJuly 2025 Breakouts & Verified High Yield Trade Plans - newser.com
Why Insight Molecular Diagnostics Inc. (7OC0) stock stays resilient2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
Published on: 2025-11-19 17:04:49 - newser.com
Published on: 2025-11-19 13:52:26 - newser.com
Published on: 2025-11-19 13:17:14 - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock worth holding before Fed meetingMarket Volume Report & Capital Efficient Trade Techniques - newser.com
How Insight Molecular Diagnostics Inc. (7OC0) stock trades under stagflation2025 Sector Review & Precise Swing Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock a top pick for value investorsQuarterly Market Review & Free High Return Stock Watch Alerts - newser.com
Insight Molecular Diagnostics (IMDX) Price Target Increased by 29.23% to 7.14 - Nasdaq
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating (IMDX) - Seeking Alpha
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
There is no financial data for Insight Molecular Diagnostics Inc (IMDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):